These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 8058159)

  • 1. Beta 2-adrenergic agonist as adjunct therapy to levodopa in Parkinson's disease.
    Alexander GM; Schwartzman RJ; Nukes TA; Grothusen JR; Hooker MD
    Neurology; 1994 Aug; 44(8):1511-3. PubMed ID: 8058159
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Albuterol improves response to levodopa and increases skeletal muscle mass in patients with fluctuating Parkinson disease.
    Uc EY; Lambert CP; Harik SI; Rodnitzky RL; Evans WJ
    Clin Neuropharmacol; 2003; 26(4):207-12. PubMed ID: 12897642
    [TBL] [Abstract][Full Text] [Related]  

  • 3. "Wearing-off" and beta 2-adrenoceptor agonist in Parkinson's disease.
    Hishida R; Kurahashi K; Narita S; Baba T; Matsunaga M
    Lancet; 1992 Apr; 339(8797):870. PubMed ID: 1347877
    [No Abstract]   [Full Text] [Related]  

  • 4. Safinamide as Add-On Therapy to Levodopa in Mid- to Late-Stage Parkinson's Disease Fluctuating Patients: Post hoc Analyses of Studies 016 and SETTLE.
    Cattaneo C; Sardina M; Bonizzoni E
    J Parkinsons Dis; 2016; 6(1):165-73. PubMed ID: 26889632
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adding a dopamine agonist to preexisting levodopa therapy vs. levodopa therapy alone in advanced Parkinson's disease: a meta analysis.
    Talati R; Baker WL; Patel AA; Reinhart K; Coleman CI
    Int J Clin Pract; 2009 Apr; 63(4):613-23. PubMed ID: 19222614
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The effectiveness and tolerance of piribedil as adjunct therapy to levodopa in patients with Parkinson's disease: a nine month follow up].
    Salazar Tortolero G; Wix Ramos R; Salazar Aladrén P; Jiménez León JC
    Rev Neurol; 2004 Apr 16-30; 38(8):715-9. PubMed ID: 15122540
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled study.
    Bracco F; Battaglia A; Chouza C; Dupont E; Gershanik O; Marti Masso JF; Montastruc JL;
    CNS Drugs; 2004; 18(11):733-46. PubMed ID: 15330687
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Rasagiline in daily clinical use. Results of a treatment study of Parkinson patients with a combination treatment].
    Jost WH; Klasser M; Reichmann H
    Fortschr Neurol Psychiatr; 2008 Oct; 76(10):594-9. PubMed ID: 18833504
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pramipexole in Parkinson's disease. A short-term study using the combined levodopa-dopamine agonist test.
    Fabbrini G; Barbanti P; Aurilia C; Pauletti C; Meco G
    Funct Neurol; 2002; 17(4):199-201. PubMed ID: 12675263
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Double-blind, placebo-controlled study of entacapone in levodopa-treated patients with stable Parkinson disease.
    Olanow CW; Kieburtz K; Stern M; Watts R; Langston JW; Guarnieri M; Hubble J;
    Arch Neurol; 2004 Oct; 61(10):1563-8. PubMed ID: 15477510
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Levodopa treatment does not affect low-dose apomorphine test in patients with Parkinson's disease.
    Happe S; Tings T; Helmschmied K; Neubert K; Wuttke W; Paulus W; Trenkwalder C
    Mov Disord; 2004 Dec; 19(12):1511-5. PubMed ID: 15390061
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modulatory effect of clozapine on levodopa response in Parkinson's disease: a preliminary study.
    Arevalo GJ; Gershanik OS
    Mov Disord; 1993 Jul; 8(3):349-54. PubMed ID: 8341300
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term treatment with high-dosage bromocriptine in advanced Parkinson's disease.
    Jansen EN; Meerwaldt JD
    Adv Neurol; 1987; 45():539-42. PubMed ID: 3103396
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and tolerability of entacapone in patients with Parkinson's disease treated with levodopa plus a dopamine agonist and experiencing wearing-off motor fluctuations. A randomized, double-blind, multicentre study.
    Fénelon G; Giménez-Roldán S; Montastruc JL; Bermejo F; Durif F; Bourdeix I; Péré JJ; Galiano L; Schadrack J
    J Neural Transm (Vienna); 2003 Mar; 110(3):239-51. PubMed ID: 12658373
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term responses of Parkinson's disease to levodopa therapy.
    Rinne UK; Sonninen V; Siirtola T; Marttila R
    J Neural Transm Suppl; 1980; (16):149-56. PubMed ID: 6776234
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improvement of levodopa-induced dyskinesia by propranolol in Parkinson's disease.
    Carpentier AF; Bonnet AM; Vidailhet M; Agid Y
    Neurology; 1996 Jun; 46(6):1548-51. PubMed ID: 8649546
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Beta-adrenergic sensitivity in Parkinson's disease: effect of levodopa treatment.
    Durrieu G; Rispail Y; Chatelut E; Berlan M; Rascol A; Montastruc JL; Montastruc P
    Clin Neuropharmacol; 1990 Dec; 13(6):492-9. PubMed ID: 2177376
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rasagiline adjunct therapy in patients with Parkinson's disease: post hoc analyses of the PRESTO and LARGO trials.
    Elmer LW
    Parkinsonism Relat Disord; 2013 Nov; 19(11):930-6. PubMed ID: 23849501
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Levodopa and the progression of Parkinson's disease.
    Fahn S; Oakes D; Shoulson I; Kieburtz K; Rudolph A; Lang A; Olanow CW; Tanner C; Marek K;
    N Engl J Med; 2004 Dec; 351(24):2498-508. PubMed ID: 15590952
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lisuride, a dopamine agonist in the treatment of early Parkinson's disease.
    Rinne UK
    Neurology; 1989 Mar; 39(3):336-9. PubMed ID: 2927639
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.